A carregar...
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
BACKGROUND: Progression-free survival (PFS) exhibits suboptimal performance as the surrogate endpoint for overall survival (OS) in trials studying immune checkpoint inhibitors (ICIs). Here we propose a novel surrogate endpoint, modified PFS (mPFS), which omits the events of disease progression (but...
Na minha lista:
| Publicado no: | J Immunother Cancer |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8021890/ https://ncbi.nlm.nih.gov/pubmed/33795385 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-002114 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|